endpts.com·Apr 28, 2026
Coulteron Biopharma has successfully raised $125 million from major biotech investors to pursue a new approach to SIK inhibition, following its spinout from Galapagos.
Coultreon Biopharma's recent success in raising $125 million from prominent biotech investors highlights a significant investment signal in the area of SIK (Salt-Inducible Kinase) inhibition. This suggests a growing interest and potential opportunity in developing novel therapeutic approaches targeting this pathway, which could be a strategic area for further investment or partnership exploration in healthtech and biotech sectors.